Interview with David Ross Camidge, MD, PhD, Assistant Professor, University of Colorado, Denver, Colorado, USA Non-small cell lung cancer is currently the single biggest killer from cancer of any disease in the world. It's called non-small cell lung cancer to distinguish it from another rarer type of lung cancer called small cell, which behaves very differently and is treated very differently. Professor Thomas J. Lynch, MD, Director of Yale Cancer Centre, discusses the oral, once daily investigational targeted therapy Afatinib, and the impact it could have for patients with non-small cell lung cancer who have the EGFR mutation. If you are a journalist and would like more information please visit: http://www.newshome.com/oncology/ If you are a healthcare professional and would like more information please visit: http://www.inoncology.com/
